143 related articles for article (PubMed ID: 38287554)
21. Safety of urate-lowering therapies: managing the risks to gain the benefits.
Keenan RT
Rheum Dis Clin North Am; 2012 Nov; 38(4):663-80. PubMed ID: 23137576
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Sun SS; Zhang DH; Shi Y; Lin CJ; Lin JY
J Clin Pharm Ther; 2020 Aug; 45(4):729-742. PubMed ID: 32406077
[TBL] [Abstract][Full Text] [Related]
23. Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
Premachandra KH; Day RO; Roberts DM
Curr Opin Nephrol Hypertens; 2021 Mar; 30(2):245-251. PubMed ID: 33399392
[TBL] [Abstract][Full Text] [Related]
24. New therapeutic approach to hyperuricemia and gout in the light of recommendations.
Lioté F
Joint Bone Spine; 2016 Jul; 83(4):376-80. PubMed ID: 27085801
[No Abstract] [Full Text] [Related]
25. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
Dalbeth N; Saag KG; Palmer WE; Choi HK; Hunt B; MacDonald PA; Thienel U; Gunawardhana L
Arthritis Rheumatol; 2017 Dec; 69(12):2386-2395. PubMed ID: 28975718
[TBL] [Abstract][Full Text] [Related]
26. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
[TBL] [Abstract][Full Text] [Related]
28. Associations of hyperuricemia, gout, and UA-lowering therapy with the risk of fractures: A meta-analysis of observational studies.
Zong Q; Hu Y; Zhang Q; Zhang X; Huang J; Wang T
Joint Bone Spine; 2019 Jul; 86(4):419-427. PubMed ID: 30910706
[TBL] [Abstract][Full Text] [Related]
29. Pharmacist-managed titration of urate-lowering therapy to streamline gout management.
Huang IJ; Liew JW; Morcos MB; Zuo S; Crawford C; Bays AM
Rheumatol Int; 2019 Sep; 39(9):1637-1641. PubMed ID: 31147732
[TBL] [Abstract][Full Text] [Related]
30. Why better treatment of gout is needed.
So AK
Clin Exp Rheumatol; 2016; 34(4 Suppl 98):63-5. PubMed ID: 27586807
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
[TBL] [Abstract][Full Text] [Related]
32. Febuxostat.
Hair PI; McCormack PL; Keating GM
Drugs; 2008; 68(13):1865-74. PubMed ID: 18729537
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
[No Abstract] [Full Text] [Related]
34. Update on gout 2012.
So A; Busso N
Joint Bone Spine; 2012 Dec; 79(6):539-43. PubMed ID: 23165182
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis.
Li S; Yang H; Guo Y; Wei F; Yang X; Li D; Li M; Xu W; Li W; Sun L; Gao Y; Wang Y
Sci Rep; 2016 Sep; 6():33082. PubMed ID: 27605442
[TBL] [Abstract][Full Text] [Related]
36. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
37. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
38. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Fan M; Liu J; Zhao B; Wu X; Li X; Gu J; Schlesinger N
Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
[TBL] [Abstract][Full Text] [Related]
39. Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.
Kvasnička A; Friedecký D; Brumarová R; Pavlíková M; Pavelcová K; Mašínová J; Hasíková L; Závada J; Pavelka K; Ješina P; Stibůrková B
Arthritis Res Ther; 2023 Dec; 25(1):234. PubMed ID: 38042879
[TBL] [Abstract][Full Text] [Related]
40. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
